2024 April 11 release (#27)

vanallenlab · Apr 11, 2024 · 9b2e192 · 9b2e192
1 parent 87d9b7e
commit 9b2e192
Show file tree

Hide file tree

Showing 2 changed files with 2,272 additions and 1,055 deletions.
diff --git a/docs/content-changelog.md b/docs/content-changelog.md
@@ -1,6 +1,19 @@
 # Content Changelog
 The following changes have been made to the content catalogued within the Molecular Oncology Almanac knowledge base.
 
+## April 2024 release
+Added entries:
+- (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with acute lymphoid leukemia.
+- (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with chronic myeloid leukemia.
+- (FDA) BCR::ABL1 and sensitivity to ponatinib in combination with chemotherapy for patients with acute lymphoid leukemia.
+- (FDA) BCR::ABL1 and sensitivity to ponatinib for patients with acute lymphoid leukemia.
+
+Revised entries:
+- The therapeutic strategy for two records with `ROS inhibition` were changed to `ROS1 inhibition`
+- _MRE11A_ somatic variants and sensitivity to enzalutamide in combination with talazoparib for patients with prostate cancer was updated to have the gene symbol be `MRE11`
+
+All records were also updated to have a `_deprecated` field, which is a boolean value to hide the record from appearing on https://moalmanac.org. 
+
 ## March 2024 release
 Added entries:
 - (FDA) _ALK_ fusions and sensitivity to crizotinib for patients with anaplastic large cell lymphoma.